Opendata, web and dolomites

TLA-Gut SIGNED

Novel Personalized Cellular Therapy Approach for Immune Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TLA-Gut project word cloud

Explore the words cloud of the TLA-Gut project. It provides you a very rough idea of what is the project "TLA-Gut" about.

institutet    therapy    clinical    commercialise    caused    chemotaxis       positioned    remaining    disease    proof    vivo    burden    trial    leukapheresis    induce    aligned    patients    karolinska    poses    create    gut    threatening    globally    clinicians    therapies    imids    release    commercialisation    risk    gap    sweden    maintained    completion    market    socio    migrate    exaggerated    personalized    safe    direct    60    tla    exists    praxis    cytokines    efficient    first    ibd    immune    removing    belongs    inflammatory    tissues    healthcare    stockholm    therapeutic    medical    demand    opportunity    bowel    efficacy    cells    group    once    causing    triggered    carry    life    treatments    business    satiate    shown    imbalance    treat    inflammation    rate    mediated    close    strategy    device    regulatory    performed    blood    internationally    billion    treatment    site    economic    remission    patient    date    proven    diseases    enabler    option   

Project "TLA-Gut" data sheet

The following table provides information about the project.

Coordinator
TLA TARGETED IMMUNOTHERAPIES AB 

Organization address
address: EKONOMILANKEN AB BOX 726
city: SOLLENTUNA
postcode: 191 27
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.tlatherapies.com/
 Total cost 3˙850˙000 €
 EC max contribution 2˙695˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TLA TARGETED IMMUNOTHERAPIES AB SE (SOLLENTUNA) coordinator 2˙695˙000.00

Map

 Project objective

This project will commercialise TLA Gut - the novel medical device for the treatment of Inflammatory Bowel Disease (IBD). IBD belongs to the group of Immune Mediated Inflammatory Diseases (IMIDs) caused and maintained by an exaggerated inflammatory response triggered by an imbalance of the immune system. Research at Karolinska Institutet in Sweden has shown that IMIDs are caused by increase in specific inflammatory cells, which migrate to the site of inflammation by chemotaxis and induce disease-causing inflammation through release of cytokines in tissues. TLA Gut is a globally unique technology, and the first medical device with a proven clinical efficacy in removing those disease-causing cells from the blood of the patient through therapeutic leukapheresis. Today, the development and commercialisation of new therapies for IBD is in great demand among clinicians and their patients as current treatments offer an overall long-term remission rate of only 50-60% and carry the risk of life-threatening side effects. There exists a strong business opportunity for a therapy that would create a new and personalized way to treat IBD. TLA Gut is positioned to satiate this demand. To date, TLA Gut in vivo proof of concept has been established in a Phase I/II clinical trial on IBD patients in Stockholm. In the project, the Phase III study will be performed together with regulatory development work required to get market access upon completion of the project. IBD poses a significant socio-economic burden internationally. In Europe, a direct healthcare cost of IBD is estimated to € 4.6–5.6 billion per year. Once introduced in the clinical praxis across the EU, TLA Gut will be a safe and cost-efficient treatment option for IBD patients. The overall business strategy of TLA is aligned to close the remaining clinical and regulatory gap to the market for TLA Gut and commercialise the medical device. The project is the key enabler of this strategy.

 Deliverables

List of deliverables.
Project website created and launched Websites, patent fillings, videos etc. 2019-11-14 10:13:28

Take a look to the deliverables list in detail:  detailed list of TLA-Gut deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TLA-GUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TLA-GUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More